Skip to main content

Table 1 Characteristics of the included studies

From: Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials

Author/published year

Induction arms (randomized)

Induction sample size

Induction regimen

Induction Cycles

Dose of Bevacizumab

Maintenance arms (randomized)

Maintenance sample size

Primary endpoint

Secondary endpoint

Patel, 2013 (PointBreak) [14]

Pem + Cb + Bev

(randomized)

442

Pem 500 mg/m2, Cb AUC 6, Bev 15 mg/kg, day 1 every 3 weeks

4

15 mg/kg

Pem + Bev

292

OS

PFS, ORR, DCR, TTPD, toxicity

 

Pac + Cb + Bev

(randomized)

443

Pac 200 mg/m2, Cb AUC 6, Bev 15 mg/kg, day 1 every 3 weeks

  

Bev

298

 

–

Zinner, 2015 (PRONOUNCE) [15]

Pem + Cb

(randomized)

182

Pem 500 mg/m2, Cb AUC 6, day 1 every 3 weeks

4

15 mg/kg

Pem

121

PFS without grade 4 toxicity

PFS, OS, ORR, DCR, safety

 

Pac + Cb + Bev

(randomized)

179

Pac 200 mg/m2, Cb AUC 6, Bev 15 mg/kg, day 1 every 3 weeks

  

Bev

113

  

Galetta, 2015 (ERACLE) [16]

Pem + Cis

(randomized)

60

Pem 500 mg/m2, Cis 75 mg/m2, day 1 every 3 weeks

6

15 mg/kg

Pem

44

QOL

PFS, OS, ORR, safety

 

Pac + Cb + Bev

(randomized)

58

Pac 200 mg/m2, Cb AUC 6

Bev 15 mg/kg, day 1 every 3 weeks

  

Bev

30

  

Barlesi, 2014 (AVAPERL)

Pem + Cis + Bev

376

Pem 500 mg/m2, Cis 75 mg/m2, Bev 7.5 mg/kg, day 1 every 3 weeks

4

7.5 mg/kg

Pem + Bev

(randomized)

128

PFS

OS, ORR, DOR

      

Bev

(randomized)

125

  

Ramalingam, 2019 (EA5508) [12]

Pac + Cb + Bev

1432

Pac 200 mg/m2, Cb AUC 6, Bev 15 mg/kg, day 1 every 3 weeks

4

15 mg/kg

Bev

(randomized)

287

OS

PFS, ORR, safety

      

Pem

(randomized)

294

  
      

Pem + Bev

(randomized)

293

  

Seto, 2019 (COMPASS) [11]

Pem + Cb + Bev

907

Pem 500 mg/m2, Cb AUC 6, Bev 15 mg/kg, day 1 every 3 weeks

4

15 mg/kg

Bev

(randomized)

295

OS (from Random Assignment)

PFS and OS (from induction therapy), safety

      

Pem + Bev

(randomized)

299

  
  1. Abbreviation: AUC Area under the curve; Bev Bevacizumab; Cb Carboplatin; Cis Cisplatin; DCR Disease control rate; DOR Duration of response; ORR Objective response rate; OS Overall survival; Pac Paclitaxel; Pem Pemetrexed; PFS Progress free survival; QOL Quality of life; TTPD Time to progressive disease